Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.
Amedisys Inc (NASDAQ: AMED) provides essential home healthcare, hospice, and high-acuity care services across the United States. This news hub offers investors and industry professionals direct access to verified corporate announcements and financial updates from the home healthcare leader.
Track material developments including quarterly earnings reports, regulatory filings, clinical program expansions, and strategic partnerships. Our curated collection features official press releases, SEC disclosures, and market-moving updates - all organized chronologically for efficient research.
Key content categories include financial performance updates, Medicare/Medicaid compliance changes, care center acquisitions, leadership appointments, and clinical quality initiatives. Bookmark this page for real-time access to operational milestones that shape AMED's position in the $300B home healthcare market.
For stakeholders monitoring the shift toward value-based care models, this resource simplifies tracking of Amedisys' evolving service offerings and regulatory compliance status. Visit regularly to stay informed about critical developments affecting one of America's largest home health providers.
Amedisys, Inc. (NASDAQ: AMED) reported strong financial results for Q1 2021, with net service revenue increasing by $45.4 million to $537.1 million compared to $491.7 million in Q1 2020. Net income rose to $49.9 million ($1.50 per diluted share) from $31.8 million ($0.96 per diluted share) the previous year. Adjusted EBITDA also saw growth, reaching $78.6 million versus $53.3 million in 2020. The company updated its 2021 guidance, projecting revenue between $2.302 billion and $2.342 billion, while adjusted EBITDA is expected to range from $342 million to $352 million.
Amedisys, Inc. (NASDAQ: AMED) is launching the Home Health Advanced Program in collaboration with Sound Physicians, set to begin in mid-May 2021. This initiative targets Medicare FFS patients with specific diagnoses and acuity levels, offering personal care and telemedicine services at no extra cost. Amedisys emphasizes its commitment to high-quality home care for higher acuity patients, expanding its Personal Care Network across 39 states with 1,500 agencies. The program is designed to improve care quality and reduce costs for patients transitioning from hospitals to home.
Amedisys, Inc. (NASDAQ: AMED) will announce its first-quarter results for the period ending March 31, 2021, on April 28, 2021. An investor conference call is scheduled for April 29, 2021, at 11:00 a.m. ET to discuss these results. Interested parties can join the call by dialing (877) 524-8416 for toll-free or (412) 902-1028 for toll access. A replay will be available until May 29, 2021. Amedisys is a prominent provider of home health, hospice, and personal care services, serving over 418,000 patients annually with a network of 514 care centers across the U.S.
Amedisys (NASDAQ: AMED) has announced a definitive agreement to acquire regulatory assets for home health care operations in Randolph County, N.C. The acquisition, expected to close on April 30, 2021, allows Amedisys to provide certified home health services to 31,000 Medicare and Medicare Advantage enrollees within a 50-mile radius. Following the acquisition, Amedisys will establish a start-up care center, further enhancing its footprint as the second-largest home health care provider in the U.S., with 320 locations across 34 states.
Amedisys (NASDAQ: AMED) has repurchased approximately $73 million in stock since March 1, 2021, following a $100 million buyback authorization from late 2020. CEO Paul Kusserow stated that this was an advantageous move for shareholders and highlighted the company’s strong cash flow and low leverage, ensuring it won't affect their acquisition strategy. The company remains focused on expanding its home health and hospice services, with a robust pipeline for future growth.
Amedisys, a leading home health and hospice company, announced that CEO Paul B. Kusserow will present at two upcoming conferences: the 42nd Annual Raymond James Institutional Investors Conference on March 3, 2021, at 9:10 a.m. ET, and the Barclays Global Healthcare Conference on March 9, 2021, at 9:45 a.m. ET. Investors can access a live webcast of these presentations via the company’s website. Amedisys serves over 418,000 patients annually and operates 514 care centers across 39 states.
Amedisys has announced the promotions of Christopher Gerard to President and Chief Operating Officer and Scott Ginn to Executive Vice President and Chief Financial Officer, effective immediately. Gerard has led significant growth, expanding Amedisys to 514 care centers across 39 states and achieving an impressive Quality of Patient Care Star score of 4.33. Ginn has been pivotal in growing the company's revenue from $500 million to over $2 billion. Both executives express excitement about leading the company forward while emphasizing quality patient care.
Amedisys reported strong financial results for Q4 2020, with a net service revenue of $550.7 million, up $50 million from 2019. Net income surged to $45.2 million ($1.36 per diluted share) compared to $27.7 million ($0.83) in the prior year. For the full year 2020, net service revenue reached $2.0715 billion, an increase of $115.9 million year-over-year. Amedisys provided optimistic 2021 guidance projecting net service revenue between $2.275 billion to $2.315 billion and adjusted EBITDA of $315 million to $325 million.
Amedisys, Inc. (NASDAQ: AMED) announced it will release its fourth quarter and full-year financial results for 2020 after market close on February 24, 2021. A conference call is scheduled for February 25, 2021 at 11:00 a.m. ET to discuss these results. Interested participants can join via toll-free number (877) 524-8416 or view a live webcast on the company's website. Amedisys provides personalized home healthcare services and partners with over 2,900 hospitals and 78,000 physicians across the U.S.
Amedisys (NASDAQ: AMED) announces a collaboration with Option Care Health (NASDAQ: OPCH) to provide COVID antibody infusion therapy in long-term care facilities. The pilot program, starting in Indianapolis and Valparaiso, Indiana, aims to enhance access to vital therapies for high-risk COVID-19 patients. Amedisys will manage care coordination, while Option Care Health will oversee clinical pharmacy operations and distribute Bamlanivimab. This partnership reflects both companies' commitment to addressing critical healthcare challenges during the pandemic.
FAQ
What is the current stock price of Amedisys (AMED)?
What is the market cap of Amedisys (AMED)?
